Results 31 to 40 of about 955 (158)

Aberrant ROS Served as an Acquired Vulnerability of Cisplatin‐Resistant Lung Cancer

Oxidative Medicine and Cellular Longevity, Volume 2022, Issue 1, 2022., 2022
Lung cancer has become a global health issue in recent decades. Approximately 80‐85% of cases are non‐small‐cell lung cancer (NSCLC). Despite the high rate of resistance, cisplatin‐base chemotherapy is still the main treatment for NSCLC patients. Thus, overcoming cisplatin resistance is urgently needed in NSCLC therapy. In this study, we identify NADPH
Qian Xin, Qinghong Ji, Ying Zhang, Weihong Ma, Baoqing Tian, Yanli Liu, Yunsong Chen, Fei Wang, Ran Zhang, Xingwu Wang, Jupeng Yuan, Gaocai Li   +11 more
wiley   +1 more source

PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa [PDF]

Molecular Cancer Therapeutics, 2013
Abstract Targeting p53 by the small-molecule PRIMA-1Met/APR-246 has shown promising preclinical activity in various cancer types. However, the mechanism of PRIMA-1Met–induced apoptosis is not completely understood and its effect on multiple myeloma cells is unknown.
Manujendra N, Saha, Hua, Jiang, Yijun, Yang, Donna, Reece, Hong, Chang   +4 more
openaire   +4 more sources

Small molecule induced reactivation of mutant p53 in cancer cells [PDF]

, 2013
The p53 cancer mutant Y220C is an excellent paradigm for rescuing the function of conformationally unstable p53 mutants because it has a unique surface crevice that can be targeted by small-molecule stabilizers.
Adams, Alan R. Fersht, Andreas C. Joerger, Boeckler, Brown, Bullock, Bullock, Chipuk, Chuckowree, Cook, Dearth, Di Como, Emsley, Endo, Foster, Gannon, Green, Hengartner, Irina S. Chuckowree, Jahangir Amin, Joerger, Joerger, Joerger, Joerger, John Spencer, Johnson, Kaar, Kabsch, Kojima, Kojima, Lambert, Lane, Legros, Leslie, Liu, Newhouse, Oda, Petitjean, Rainer Wilcken, Rippin, Speidel, Spencer, Spencer, Spencer, Spencer, Spencer, Taylor, Van Maerken, Vassilev, Villunger, Vousden, Walerych, Wang, Wattel, Wilcken, Wilcken, Wolter, Xiangrui Liu, Yu   +58 more
core   +2 more sources

Pan‐Cancer Pyroptosis Analyses Identified Novel Immunology and Chemotherapy‐Related Prognostic Signatures in Cancer Subtypes

Journal of Oncology, Volume 2022, Issue 1, 2022., 2022
Despite mounting evidence linking pyroptotic cell death to tumor growth, the clinical significance and disease mechanism of pyroptosis in cancer remain uncertain. In this study, we established a unique gene signature (π signature) that can be used as a predictive and prognostic tool in pyroptosis‐related cancer subtypes.
Canrong Li, Cha Lin, Xiaoduo Xie, Quan Cheng   +3 more
wiley   +1 more source

On the Heterogeneous Nature of Cisplatin‐1‐Methyluracil Complexes: Coexistence of Different Aggregation Modes and Partial Loss of NH3 Ligands as Likely Explanation

ChemistryOpen, Volume 10, Issue 1, Page 28-45, January 2021., 2021
Multiple condensation reactions of mononuclear 1‐methyl uracilato (1MeU) complexes of Cisplatin, and numerous side reactions, lead to a heterogeneous mixture of products, as shown by 1H‐NMR and ESI‐MS Abstract The conversion of the 1 : 1‐complex of Cisplatin with 1‐methyluracil (1MeUH), cis‐[Pt(NH3)2(1MeU‐N3)Cl] (1 a) to the aqua species cis‐[Pt(NH3)2 ...
Sonja Pullen, Alexander Hegmans, Wolf G. Hiller, André Platzek, Eva Freisinger, Bernhard Lippert   +5 more
wiley   +1 more source

Small molecules as research tools for studying the biology of the tumour suppressor p53 [PDF]

, 2011
p53 is a potent tumour suppressor that is inactivated in the majority, if not all human cancers. In about 50% of the cases, the gene is mutated and in the rest it is rendered inactive mainly by deregulation of its negative regulators such as Hdm2 and
Spinnler, Clemens
core   +1 more source

PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53 [PDF]

Clinical Cancer Research, 2011
Abstract Purpose: Small cell lung cancer (SCLC) is a highly malignant disease with poor prognosis, necessitating the need to develop new and efficient treatment modalities. PRIMA-1Met (p53-dependent reactivation of massive apoptosis), also known as APR-246, is a small molecule, which restores tumor suppressor function to mutant p53 ...
Zandi, Roza, Selivanova, Galina, Christensen, Camilla Laulund, Gerds, Thomas Alexander, Willumsen, Berthe Marie, Poulsen, Hans Skovgaard   +5 more
openaire   +3 more sources

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML [PDF]

, 2020
Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46% of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary induction failure, high risk of relapse, and dismal prognosis.
al., et, DiPersio, John F., Rettig, Michael P., Vadakekolathu, Jayakumar   +3 more
core   +8 more sources

TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment [PDF]

, 2015
International audienceLung cancer is a serious public health problem. Although there has been significant progress in chemotherapy, non-small cell lung cancer is still resistant to current treatments, primarily because of the slow rate of cell ...
Boutard, Tifenn, Jacquot, Catherine, Le Palabe, Julie, Malleter, Marine, Roussakis, Christos, Rousseau, Bénédicte, Sakanyan, Vehary, Tomasoni, Christophe   +7 more
core   +5 more sources

Potential Role of Induced Pluripotent Stem Cells (IPSCs) for Cell-Based Therapy of the Ocular Surface [PDF]

, 2015
The integrity and normal function of the corneal epithelium are crucial for maintaining the cornea's transparency and vision. The existence of a cell population with progenitor characteristics in the limbus maintains a dynamic of constant epithelial ...
Casaroli Marano, Ricardo Pedro, Edel, Michael John, Martínez-Conesa, Eva M., Nieto-Nicolau, Nuria, Álvarez Palomo, Ana Belén   +4 more
core   +3 more sources